A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction.

Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol (2007) 0.87

The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations. J Mol Diagn (2007) 0.87

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Sci Rep (2014) 0.85

Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature (1961) 23.98

Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet (1992) 11.38

Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46

Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med (1997) 2.81

Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54

Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol (1997) 1.83

Chromosomal basis of X chromosome inactivation: identification of a multigene domain in Xp11.21-p11.22 that escapes X inactivation. Proc Natl Acad Sci U S A (1998) 1.43

Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res (1997) 1.32

An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci U S A (1998) 1.22

X-linked genetic factors regulate hematopoietic stem-cell kinetics in females. Blood (2000) 1.21

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol (1997) 1.17

Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. Am J Pathol (1998) 1.17

Isolation and characterization of XE169, a novel human gene that escapes X-inactivation. Hum Mol Genet (1994) 1.12

Assessment of mechanism of acquired skewed X inactivation by analysis of twins. Blood (2001) 1.06

Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol (1996) 1.03

Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood (1990) 1.02

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood (1989) 1.00

Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res (2000) 0.99

Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol (1999) 0.98

Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol (2001) 0.98

The murine Xe169 gene escapes X-inactivation like its human homologue. Nat Genet (1994) 0.96

X chromosome inactivation in the normal female genital tract: implications for identification of neoplasia. Cancer Res (1995) 0.95

Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol (1997) 0.94

Mosaic pattern of maternal and paternal keratinocyte clones in normal human epidermis revealed by analysis of X-chromosome inactivation. J Invest Dermatol (2001) 0.91

Acquired skewing of Lyonization remains stable for a prolonged period in healthy blood donors. Leukemia (2002) 0.90

Evidence for clonal origin of neoplastic neuronal and glial cells in gangliogliomas. Am J Pathol (1997) 0.90

Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay. Lab Invest (2000) 0.89

Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay. Leukemia (1996) 0.84

Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood (1999) 0.83

Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood (1998) 0.81

Monoclonality of normal human colonic crypts. Pathol Int (1995) 0.78

Clinical outcome in three patients with myelodysplastic syndrome showing polyclonal hematopoiesis. Acta Haematol (1999) 0.78

Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90

Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol (2012) 3.81

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol (2011) 2.48

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood (2006) 2.46

Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol (2010) 2.24

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer (2009) 2.12

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2012) 2.01

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol (2009) 1.98

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood (2003) 1.84

The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. EMBO J (2012) 1.76

A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med (2013) 1.75

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75

Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood (2009) 1.74

Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol (2009) 1.64

Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica (2006) 1.61

Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.58

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol (2008) 1.55

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53

ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res (2006) 1.52

Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions. Leuk Res (2007) 1.50

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2012) 1.43

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol (2009) 1.41

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40

Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 1.39

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34

A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest (2005) 1.33

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood (2013) 1.26

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica (2012) 1.24

MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev (2010) 1.21

Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood (2012) 1.18

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood (2012) 1.15

Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosis. Exp Cell Res (2004) 1.15

Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev (2010) 1.14

Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol (2009) 1.07

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol (2013) 1.07

Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin Cancer Res (2005) 1.05

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica (2010) 1.05

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood (2006) 1.05

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood (2010) 1.04

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood (2010) 1.03

Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica (2004) 1.01

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica (2010) 1.01

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol (2007) 1.00

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood (2010) 0.99

Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol (2009) 0.99

Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha. Blood (2007) 0.98

High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood (2012) 0.96

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood (2010) 0.96

Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol (2010) 0.96

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol (2013) 0.96

Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol (2012) 0.96

MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med (2013) 0.95

The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. Blood (2012) 0.95

Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol (2005) 0.92

Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med (2009) 0.92

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica (2007) 0.92

The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. Blood (2005) 0.92

TET proteins in malignant hematopoiesis. Cell Cycle (2009) 0.92

Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol (2005) 0.90

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2014) 0.90

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One (2013) 0.90

Gfi1 ubiquitination and proteasomal degradation is inhibited by the ubiquitin ligase Triad1. Blood (2007) 0.89

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol (2010) 0.89

Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica (2010) 0.89

Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol (2008) 0.89

High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients. Blood (2011) 0.88

Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol (2002) 0.88